TSLP

TSLP

TSLP 詳細

Molecule Name
Thymic stromal lymphopoietin
分子の別称
TSLP
Drug Development Progress
治験薬の数28
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Thymic stromal lymphopoietin,TSLP
バックグランド
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine involved in the pathology of inflammatory skin diseases, and is widely expressed by epithelial cells. Human TSLP cDNA encodes a 159 amino acid (aa) residue precursor protein with a 28 aa signal sequence (4, 5). Human TSLP has been shown to developing nondeletional central tolerance, amplifying epithelium-induced class switching, inducing atopic diseases and maintaining intestinal noninflammatory environment. Among diverse cells responding to Human TSLP, CD11c+ dendritic cells are the most obviously characterized target cells.

TSLP 製品リスト

Species
  • Human(11)
  • Cynomolgus(3)
  • Mouse(2)
  • Rat(1)
Tag
  • His Tag(8)
  • His Tag & Avi Tag(4)
  • Fc Tag(2)
  • Fc Tag & Avi Tag(2)
  • Mouse IgG Fc Tag(1)
Host
  • HEK293(17)
Conjugate
  • Unconjugated(10)
  • Biotin-labeled(6)
  • PE Labeled(1)
Grade
  • RUO(16)
  • PG (pre-GMP)(1)
Low Endotoxin
  • Yes(6)
  • No(11)
MoleculeCat. No.Product Name種HostStructurePurityActivitySize&Price
TSLP
Human TSLP Protein (R127A, R130A), His Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLIFlow

$380.00

100ug
TSLP
Human TSLP Protein, His Tag, premium grade
Human
HEK293
MSMALSSDS-PAGE
ELISASPRBLIFlowCELL BASE

$415.00

100ug
TSLP
HOTAvitag
TSP-H82Eb
Biotinylated Human TSLP Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLIFlow

$415.00

25ug
TSLP
Mouse TSLP Protein, His Tag (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$380.00

100ug
TSLP
Cynomolgus TSLP (R127A, R130S) Protein, His Tag, low endotoxin (Mass Spec & HPLC verified)
Cynomolgus
HEK293
HPLCSDS-PAGE
ELISABLI

$430.00

100ug
TSLP
Cynomolgus TSLP Protein, His Tag (Mass Spec & MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISABLI

$395.00

100ug
TSLP
Avitag
TSP-C82E3
Biotinylated Cynomolgus TSLP Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISABLI

$360.00

25ug
TSLP
Human TSLP Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$385.00

100ug
TSLP
Human TSLP (R127A, R130A) Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$385.00

100ug
TSLP
Human TSLP (R127A, R130A) Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$380.00

100ug
You Have Viewed 1-10 Of 17 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

How should cross-species TSLP binding be evaluated for preclinical studies?

Compare human TSLP with mouse, cynomolgus, or rat TSLP according to the intended model. Use matched variants, tags, and assay conditions because sequence and construct differences can both affect measured affinity.

Why can SPR and BLI report different apparent affinities for TSLP–TSLPR binding?

Surface density, capture orientation, Fc-related avidity, and mass transport can shift the apparent affinity. Compare candidates within the same setup and use the second platform as orthogonal confirmation.

How can I distinguish a TSLP-binding antibody from a receptor-blocking antibody?

Confirm TSLP binding by ELISA, SPR, or BLI, then test inhibition of the TSLP–TSLPR–IL-7Rα interaction. Strong binding with weak inhibition suggests a non-blocking epitope or an unfavorable binding geometry.

Why should TSLP blockers be tested against receptor-complex assembly rather than TSLP–TSLPR binding alone?

TSLP first engages TSLPR and then recruits IL-7Rα to form the signaling complex. Pairwise binding identifies direct interaction, while a TSLP/TSLPR/IL-7Rα inhibition assay tests whether the candidate disrupts complex assembly.

When should wild-type TSLP or the R127A/R130A variant be used?

R127A/R130A removes a putative furin-cleavage site and can improve stability of the full-length protein. It is useful for reproducible binding assays, while wild-type TSLP is preferable when native sequence fidelity is the primary requirement.
Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
QL-2302QL2302; QL-2302Phase 3 ClinicalQilu Pharmaceutical Co Ltd
Asthma
詳細
GB-0895GB-0895Phase 3 ClinicalGenerate Biomedicines Inc
Asthma; Immune System Diseases; Pulmonary Disease, Chronic Obstructive
詳細
TilrekimigPF-07275315Phase 3 ClinicalPfizer Inc
Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive
詳細
LunsekimigSAR-443765Phase 3 ClinicalSanofi
Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive
詳細
BosakitugTQC-2731; BSI-045B; TQC2731; ATI-045Phase 3 ClinicalBiosion Inc
Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis
詳細
SHR-1905SHR-1905; AIO-001; GSK-5784283Phase 3 ClinicalJiangsu Hengrui Medicine Co Ltd
Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis
詳細
CM-326CM-326Phase 3 ClinicalKeymed Biosciences Co Ltd
Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis
詳細
QX-008NQX-008N; QX008N; JKN-2401; JKN2401; SNCA008; SNCA-008Phase 3 ClinicalQyuns Therapeutics Co Ltd
Asthma; Pulmonary Disease, Chronic Obstructive
詳細
SolrikitugNSI-8226; MK-8226Phase 2 ClinicalMerck & Co Inc
Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Hypertension; Pulmonary Disease, Chronic Obstructive
詳細
EcleralimabCSJ-117; NOV-14Phase 2 ClinicalNovartis Pharma Ag
Asthma; Pulmonary Disease, Chronic Obstructive
詳細
HBM-9378HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378Phase 2 ClinicalHarbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
Asthma; Pulmonary Disease, Chronic Obstructive
詳細
CM-512CM512; CM-512Phase 2 ClinicalKeymed Biosciences Co Ltd
Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis
詳細
IBI-3002IBI3002; IBI-3002Phase 2 Clinical
Asthma; Dermatitis, Atopic
詳細
MG-ZG122MG-ZG122; MGZG122Phase 2 ClinicalShanghai Mabgeek Biotechnology Co Ltd
Asthma; Pulmonary Disease, Chronic Obstructive
詳細
AZD-8630AZD-8630; AMG-104Phase 2 ClinicalAmgen Inc, Astrazeneca Plc
Asthma
詳細
TAVO-101TAVO-101; TAVO101Phase 2 ClinicalTavotek Biotherapeutics (Hong Kong) Ltd
Dermatitis, Atopic; Hypersensitivity
詳細
PF-06342674RN-168; PF-6342674; PF-06342674; ZB-168Phase 1 ClinicalPfizer Inc
Diabetes Mellitus, Type 1; Multiple Sclerosis
詳細
APG273APG273; APG-273Phase 1 ClinicalApogee Therapeutics Inc
Asthma; Pulmonary Disease, Chronic Obstructive
詳細
HBM-7575HBM-7575; SKB575; SKB-575; HBM7575Phase 1 ClinicalHarbour Biomed
Dermatitis, Atopic; Inflammation
詳細
WIN-027QX027N; QX-027-N; WIN027; WIN-027Phase 1 ClinicalQyuns Therapeutics Co Ltd
Asthma; Dermatitis, Atopic
詳細
HB-0056HB-0056; HB0056Phase 1 ClinicalShanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd
Asthma; Dermatitis, Atopic; Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive
詳細
APG-333APG333; APG-333; PR018; PR-018Phase 1 ClinicalApogee Therapeutics Inc
Asthma
詳細
SAR-444765SAR444765; SAR-444765Phase 1 ClinicalSanofi
Inflammation
詳細
BSI-502BSI-502; ATI-052Phase 1 ClinicalBiosion Inc
Autoimmune Diseases of the Nervous System; Inflammation
詳細
CDX-622CDX-622Phase 1 ClinicalCelldex Therapeutics Inc
Asthma; Fibrosis; Hypersensitivity; Inflammation
詳細
STSA-1201STSA-1201; STSA1201Phase 1 ClinicalStaidson(Beijing) Biopharmaceuticals Co Ltd
Asthma
詳細
LQ043HLQ043HPhase 1 ClinicalShanghai Novamab Biopharmaceuticals Co Ltd
Asthma
詳細
GR2002GR2002Phase 1 ClinicalGenrix (Shanghai) Biopharmaceutical Co Ltd
Asthma; Dermatitis, Atopic; Nasal Polyps; Sinusitis
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
TezepelumabMEDI-9929; AMG-157ApprovedAmgen IncTezspireUnited StatesAsthmaAstrazeneca Ab2021-12-17
Anaphylaxis; Asthma; Bronchial Diseases; Carcinoma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilic Esophagitis; Granulomatosis with Polyangiitis; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Lung Diseases; Lung Diseases, Obstructive; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Respiratory Tract Diseases; Sinusitis
詳細
Customer Reviews
  • S***n2023-06-10
    We got the TSLP recombinant protein from your company. The plan was to stimulate cell in vitro to see if it can induce a TH2 response. Your company offers the most cost effective option for the TSLP protein and with good customer service and express shipping. So far we do see some level of responses in the cells, we will perform more testing to validate the effects. The quality of the protein seems quite good and worth trying.